Discounted Cash Flow (DCF) Analysis Unlevered

Provention Bio, Inc. (PRVB)

$ 7.02
-0.37 (-5.01%)
Stock DCF: - | 7.02 | undervalue

Operating Data

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ---------
Revenue (%)
EBITDA ---------
EBITDA (%)
EBIT ---------
EBIT (%)
Depreciation ---------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash ---------
Total Cash (%)
Account Receivables ---------
Account Receivables (%)
Inventories ---------
Inventories (%)
Accounts Payable ---------
Accounts Payable (%)
Capital Expenditure ---------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 7.02
Beta 2.836
Diluted Shares Outstanding 52.46
Cost of Debt
Tax Rate 0.53
After-tax Cost of Debt 4.97%
Risk-Free Rate
Market Risk Premium
Cost of Equity 14.867
Total Debt 0.71
Total Equity 368.25
Total Capital 368.96
Debt Weighting 0.19
Equity Weighting 99.81
Wacc

Build Up Free Cash

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ---------
EBITDA ---------
EBIT ---------
Tax Rate 0.00%0.70%0.00%0.53%0.31%0.31%0.31%0.31%0.31%
EBIAT ---------
Depreciation ---------
Accounts Receivable ---------
Inventories ---------
Accounts Payable ---------
Capital Expenditure ----1.11-----
UFCF ---------
WACC
PV UFCF ---------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 14.85
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -101.58
Equity Value -
Shares Outstanding 52.46
Equity Value Per Share -